
Incyte (INCY) Stock Forecast & Price Target
Incyte (INCY) Analyst Ratings
Bulls say
Incyte's strong financial outlook is bolstered by a 10% year-over-year demand growth for its leading drug, Jakafi, across various indications, which is supported by solid commercial execution and a favorable partnership with Novartis. The firm's dermatology product, Opzelura, demonstrated impressive growth with revenue of $188 million, surpassing expectations, as demand for treatments in atopic dermatitis and vitiligo increased significantly. Incyte's revised fiscal year 2025 revenue guidance, now projected between $4.23 billion and $4.32 billion, reflects positive contributions from Jakafi and other oncology products, indicating a robust overall pipeline and market position.
Bears say
Incyte faces significant risks that contribute to a negative outlook on its stock, particularly related to its leading drug, Jakafi. Eroding pricing power, potential competition, and performance issues in earlier-stage pipeline products could adversely impact revenue growth and market share. Additionally, any clinical or regulatory setbacks, as well as safety concerns related to existing and new therapies, may further diminish investor confidence and future earnings potential.
This aggregate rating is based on analysts' research of Incyte and is not a guaranteed prediction by Public.com or investment advice.
Incyte (INCY) Analyst Forecast & Price Prediction
Start investing in Incyte (INCY)
Order type
Buy in
Order amount
Est. shares
0 shares